NeoGenomics, Inc.

NeoGenomics, Inc. (NASDAQ: NEO) is a premier cancer diagnostics company headquartered in Fort Myers, Florida, specializing in cancer genetics testing and oncology data solutions through a network of CAP-accredited and CLIA-certified laboratories across the United States and the United Kingdom. Founded in 2001, the company operates through two primary divisions — Clinical Services and Pharma Services — offering one of the most comprehensive oncology-focused testing menus across the cancer continuum, including cytogenetics, FISH, flow cytometry, immunohistochemistry, molecular and next-generation sequencing (NGS) testing, and morphologic analysis. NeoGenomics serves a broad clientele that includes oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms, delivering timely and actionable diagnostic insights that guide personalized cancer care decisions. With approximately 2,200 full-time employees and revenues reaching approximately $661 million in 2024, the company continues to demonstrate consistent growth as a focused leader in precision oncology diagnostics.